A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs HTD 1801 (Primary) ; Ursodeoxycholic acid
- Indications Primary sclerosing cholangitis
- Focus Therapeutic Use
- Sponsors HighTide Biopharma
- 10 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Mar 2019.
- 03 Oct 2018 According to a HighTide Therapeutics media release, development of this study were presented at the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and Family Day at Cincinnati Children's Hospital Medical Center (CCHMC).
- 26 Sep 2018 New trial record